ProMIS Neurosciences (PMN) Schedule 13G: Wellington Management Group LLP reports beneficial ownership of 895,871 shares of ProMIS common stock, representing 9.99% of the class. The position consists of 696,378 shares held directly by Wellington Biomedical Innovation Master Investors (Cayman) II L.P. and 199,493 shares issuable upon exercise of warrants. The filers state an exercise limitation excludes 496,885 warrant shares from beneficial ownership calculations to enforce a 9.99% ownership cap. The ownership percentage is calculated using 8,967,693 shares outstanding as of March 25, 2026 per the company’s 10-K.
Positive
None.
Negative
None.
Insights
Wellington reports a near-10% passive stake via client vehicles.
Wellington Management Group LLP and affiliated entities disclose a combined beneficial stake of 895,871 shares, including 199,493 shares from exercisable warrants. The filing frames this as ownership held for clients of Wellington Investment Advisers.
Because the filing cites a 9.99% cap tied to warrant exercise limitations, actual conversion activity will be constrained by that threshold; future disclosures would show whether holders exercise warrants within that limit.
Disclosure follows Schedule 13G passive-investor format with entity attribution.
The Schedule 13G lists multiple Wellington entities and identifies record owner Wellington Biomedical Innovation Master Investors (Cayman) II L.P. It also includes a clear issuer-outstanding anchor: 8,967,693 shares outstanding per the issuer’s 10-K.
Filing emphasizes ownership classification, exercise limits on warrants, and that the position is held on behalf of advisory clients. Any change from passive to active intent would require an amended filing.
Key Figures
Beneficial ownership:895,871 sharesDirect holdings:696,378 sharesWarrants exercisable:199,493 shares+3 more
6 metrics
Beneficial ownership895,871 sharesAggregate reported beneficial ownership as of Schedule 13G
Direct holdings696,378 sharesHeld directly by Wellington Biomedical Innovation Master Investors (Cayman) II L.P.
Warrants exercisable199,493 sharesShares underlying warrants reported as part of the 895,871 total
Excluded warrant shares496,885 sharesWarrants excluded due to issuance limitation enforcing 9.99% cap
Percent of class9.99%Ownership percentage based on issuer’s 10-K share count
Shares outstanding8,967,693 sharesShares outstanding per issuer 10-K filed March 25, 2026
"199,493 Shares underlying warrants (the "Warrants") held directly"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
Beneficially ownedregulatory
"895,871 shares reported as beneficially owned on this"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Investment Advisers (IA)regulatory
"the Wellington Investment Advisers: Wellington Management Company LLP - IA"
Issuance limitationlegal
"issuance limitation that prohibits the holder from exercising the Warrants"
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
ProMIS Neurosciences, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
74346M505
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
74346M505
1
Names of Reporting Persons
Wellington Management Group LLP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
MASSACHUSETTS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
895,871.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
895,871.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
895,871.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
10.0 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
CUSIP Number(s):
74346M505
1
Names of Reporting Persons
Wellington Group Holdings LLP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
895,871.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
895,871.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
895,871.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
10.0 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
CUSIP Number(s):
74346M505
1
Names of Reporting Persons
Wellington Investment Advisors Holdings LLP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
895,871.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
895,871.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
895,871.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
10.0 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
CUSIP Number(s):
74346M505
1
Names of Reporting Persons
Wellington Management Company LLP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
895,871.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
895,871.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
895,871.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
10.0 %
12
Type of Reporting Person (See Instructions)
IA
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
ProMIS Neurosciences, Inc.
(b)
Address of issuer's principal executive offices:
Suite 200, 1920 Yonge Street, Toronto ON M4S 3E2
Item 2.
(a)
Name of person filing:
Wellington Management Group LLP
Wellington Group Holdings LLP
Wellington Investment Advisors Holdings LLP
Wellington Management Company LLP
(b)
Address or principal business office or, if none, residence:
c/o Wellington Management Company LLP, 280 Congress Street, Boston MA 02210
(c)
Citizenship:
Wellington Management Group LLP - Massachusetts
Wellington Group Holdings LLP - Delaware
Wellington Investment Advisors Holdings LLP - Delaware
Wellington Management Company LLP - Delaware
(d)
Title of class of securities:
Common Stock
(e)
CUSIP Number(s):
74346M505
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Wellington Management Group LLP may be deemed to beneficially own an aggregate of 895,871 shares (the "Shares") of Common Stock, of ProMIS Neurosciences Inc. (the "Issuer"). The 895,871 Shares reported as beneficially owned on this Schedule 13G consists of (i) 696,378 Shares held directly by Wellington Biomedical Innovation Master Investors (Cayman) II L.P., (ii) 199,493 Shares underlying warrants (the "Warrants") held directly by Wellington Biomedical Innovation Master Investors (Cayman) II L.P. The securities beneficially owned by each Filer excludes 496,885 Shares underlying Warrants which contain an issuance limitation that prohibits the holder from exercising the Warrants to the extent that after giving effect to such issuance after the exercise, the holder (together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates, including the other Filers) would beneficially own in excess of 9.99% of the Shares outstanding immediately after giving effect to the issuance of the Shares issuable upon exercise of the Warrants. As a result, Wellington Management Group LLP beneficially owns 9.99% of the outstanding Shares of the Issuer. Ownership percentages are based on approximately 8,967,693 shares of Common Stock outstanding, reported by the Issuer in its 10-K filed with the SEC on March 25, 2026.
(b)
Percent of class:
9.99 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
See the responses to Item 6 on the attached cover pages.
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
See the responses to Item 8 on the attached cover pages.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
The securities as to which this Schedule is filed are owned of record by clients of one or more investment advisers identified in Item 7 directly or indirectly owned by Wellington Management Group LLP. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. No such client is known to have such right or power with respect to more than five percent of this class of securities, except as follows:
Wellington Biomedical Innovation Master Investors (Cayman) II L.P.
Wellington Biomedical Innovation Master Investors (Cayman) II, L.P.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
Pursuant to the instructions in Item 7 of Schedule 13G, the following lists the identity and Item 3 classification of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G.
Wellington Group Holdings LLP - HC
Wellington Investment Advisors LLP - HC
Wellington Management Global Holdings, Ltd. - HC
One or more of the following investment advisers (the "Wellington Investment Advisers"):
Wellington Management Company LLP - IA
Wellington Management Canada LLC - IA
Wellington Management Singapore Pte Ltd - IA
Wellington Management Hong Kong Ltd - IA
Wellington Management International Ltd - IA
Wellington Management Japan Pte Ltd - IA
Wellington Management Australia Pty Ltd - IA
The securities as to which this Schedule is filed by Wellington Management Group LLP, as parent holding company of certain holding companies and the Wellington Investment Advisers, are owned of record by clients of the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP controls directly, or indirectly through Wellington Management Global Holdings, Ltd., the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP. Wellington Group Holdings LLP is owned by Wellington Management Group LLP.
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
What stake does Wellington Management report in ProMIS Neurosciences (PMN)?
Wellington Management Group LLP reports beneficial ownership of 895,871 shares, equal to 9.99% of the class. This total includes 696,378 shares held directly and 199,493 shares underlying warrants reported in the filing.
How is the 9.99% ownership limit applied in the filing?
The filing states an issuance limitation prevents exercise of warrants that would result in beneficial ownership above 9.99%. As a result, 496,885 warrant shares are excluded from current exercisable counts to enforce that cap.
What is the shares-outstanding figure used to calculate Wellington’s percentage?
The filing uses approximately 8,967,693 shares outstanding, based on ProMIS’s 10-K filed March 25, 2026. Wellington’s 9.99% percentage is calculated using that outstanding share count as the anchor.
Which Wellington entities are named as beneficial owners on the Schedule 13G?
The filing names Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP, and identifies record holder Wellington Biomedical Innovation Master Investors (Cayman) II L.P.
Do the filers claim voting or dispositive sole power over the shares?
The filing reports 0 sole voting power and 0 sole dispositive power; voting and dispositive authority are reported as shared among the listed filers and referenced in Item 6 and cover-page responses.
